» Articles » PMID: 15026425

Differential Regulation of Cytosolic and Peroxisomal Bile Acid Amidation by PPAR Alpha Activation Favors the Formation of Unconjugated Bile Acids

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2004 Mar 18
PMID 15026425
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In human liver, unconjugated bile acids can be formed by the action of bile acid-CoA thioesterases (BACTEs), whereas bile acid conjugation with taurine or glycine (amidation) is catalyzed by bile acid-CoA:amino acid N-acyltransferases (BACATs). Both pathways exist in peroxisomes and cytosol. Bile acid amidation facilitates biliary excretion, whereas the accumulation of unconjugated bile acids may become hepatotoxic. We hypothesized that the formation of unconjugated and conjugated bile acids from their common substrate bile acid-CoA thioesters by BACTE and BACAT is regulated via the peroxisome proliferator-activated receptor alpha (PPARalpha). Livers from wild-type and PPARalpha-null mice either untreated or treated with the PPARalpha activator WY-14,643 were analyzed for BACTE and BACAT expression. The total liver capacity of taurochenodeoxycholate and taurocholate formation was decreased in WY-14,643-treated wild-type mice by 60% and 40%, respectively, but not in PPARalpha-null mice. Suppression of the peroxisomal BACAT activity was responsible for the decrease in liver capacity, whereas cytosolic BACAT activity was essentially unchanged by the treatment. In both cytosol and peroxisomes, the BACTE activities and protein levels were upregulated 5- to 10-fold by the treatment. These effects caused by WY-14,643 treatment were abolished in PPARalpha-null mice. The results from this study suggest that an increased formation of unconjugated bile acids occurs during PPARalpha activation.

Citing Articles

Mice with a deficiency in Peroxisomal Membrane Protein 4 (PXMP4) display mild changes in hepatic lipid metabolism.

Blankestijn M, Bloks V, Struik D, Huijkman N, Kloosterhuis N, Wolters J Sci Rep. 2022; 12(1):2512.

PMID: 35169201 PMC: 8847483. DOI: 10.1038/s41598-022-06479-y.


Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.

Ghonem N, Auclair A, Hemme C, Gallucci G, de la Rosa Rodriguez R, Boyer J Clin Pharmacol Ther. 2020; 108(6):1213-1223.

PMID: 32480421 PMC: 7886378. DOI: 10.1002/cpt.1930.


Carboxy-terminal mutations of bile acid CoA:N-acyltransferase alter activity and substrate specificity.

Styles N, Shonsey E, Falany J, Guidry A, Barnes S, Falany C J Lipid Res. 2016; 57(7):1133-43.

PMID: 27230263 PMC: 4918843. DOI: 10.1194/jlr.M064428.


Bile acids: the role of peroxisomes.

Ferdinandusse S, Denis S, Faust P, Wanders R J Lipid Res. 2009; 50(11):2139-47.

PMID: 19357427 PMC: 2759819. DOI: 10.1194/jlr.R900009-JLR200.


Bile acids: regulation of synthesis.

Chiang J J Lipid Res. 2009; 50(10):1955-66.

PMID: 19346330 PMC: 2739756. DOI: 10.1194/jlr.R900010-JLR200.